{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T22:38:44Z","timestamp":1791412724782,"version":"4.3.3"},"reference-count":25,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004571","name":"Minist\u00e8re des Affaires Sociales et de la Sant\u00e9","doi-asserted-by":"publisher","award":["PHRC 11-27"],"award-info":[{"award-number":["PHRC 11-27"]}],"id":[{"id":"10.13039\/501100004571","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.annonc.2025.11.006","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T11:51:27Z","timestamp":1763639487000},"page":"403-413","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Early positron emission tomography response-adapted treatment in low-risk diffuse large B-cell lymphoma: an open-label, multicenter, randomized, noninferiority phase III trial"],"prefix":"10.1016","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3482-3331","authenticated-orcid":false,"given":"J.-M.","family":"Michot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Bologna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-N.","family":"Bastie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.V.","family":"Borght","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Bri\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Ribrag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Bommier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Peyrade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Lebras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Damaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Coso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Sibon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Bonnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3714-9824","authenticated-orcid":false,"given":"F.","family":"Morschhauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Ghesqui\u00e8res","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Fruchart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Soussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Olivier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Julian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Molina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Haioun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Tilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.annonc.2025.11.006_bib1","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1182\/blood.2021013998","article-title":"Limited-stage diffuse large B-cell lymphoma","volume":"139","author":"Hawkes","year":"2022","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.annonc.2025.11.006_bib2","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1056\/NEJMra2027612","article-title":"Diffuse large B-cell lymphoma","volume":"384","author":"Sehn","year":"2021","journal-title":"N Engl J Med"},{"issue":"suppl 5","key":"10.1016\/j.annonc.2025.11.006_bib3","doi-asserted-by":"crossref","first-page":"v116","DOI":"10.1093\/annonc\/mdv304","article-title":"Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Tilly","year":"2015","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.annonc.2025.11.006_bib4","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.6004\/jnccn.2021.0054","article-title":"NCCN Guidelines\u00ae Insights: B-cell lymphomas, version 5.2021","volume":"19","author":"Zelenetz","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"issue":"10216","key":"10.1016\/j.annonc.2025.11.006_bib5","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1016\/S0140-6736(19)33008-9","article-title":"Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial","volume":"394","author":"Poeschel","year":"2019","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.annonc.2025.11.006_bib6","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1182\/blood-2017-07-793984","article-title":"R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma","volume":"131","author":"Lamy","year":"2018","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.annonc.2025.11.006_bib7","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1200\/JCO.2007.13.6929","article-title":"Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014","volume":"26","author":"Persky","year":"2008","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.annonc.2025.11.006_bib8","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S1470-2045(11)70235-2","article-title":"CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group","volume":"12","author":"Pfreundschuh","year":"2011","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.annonc.2025.11.006_bib9","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/bloodadvances.2021004467","article-title":"Optimal timing and criteria of interim PET in DLBCL: a comparative study of 1692 patients","volume":"5","author":"Eertink","year":"2021","journal-title":"Blood Adv"},{"issue":"9","key":"10.1016\/j.annonc.2025.11.006_bib10","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1007\/s00259-013-2435-6","article-title":"An international confirmatory study of the prognostic value of early PET\/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and \u0394SUVmax","volume":"40","author":"Itti","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"10.1016\/j.annonc.2025.11.006_bib11","doi-asserted-by":"crossref","first-page":"386","DOI":"10.2967\/jnumed.110.082586","article-title":"18F-FDG PET\/CT for early response assessment in diffuse large B-cell lymphoma: poor predictive value of international harmonization project interpretation","volume":"52","author":"Cashen","year":"2011","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1016\/j.annonc.2025.11.006_bib12","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/bjh.13389","article-title":"Response-adapted therapy for aggressive non-Hodgkin's lymphomas based on early [18F] FDG-PET scanning: ECOG-ACRIN Cancer Research Group study (E3404)","volume":"170","author":"Swinnen","year":"2015","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1016\/j.annonc.2025.11.006_bib13","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1093\/annonc\/mdi272","article-title":"FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma","volume":"16","author":"Mikhaeel","year":"2005","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.annonc.2025.11.006_bib14","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1200\/JCO.2008.16.0861","article-title":"Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review","volume":"27","author":"Terasawa","year":"2009","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.annonc.2025.11.006_bib15","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","year":"2013","journal-title":"J Am Med Assoc"},{"issue":"20","key":"10.1016\/j.annonc.2025.11.006_bib16","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.annonc.2025.11.006_bib17","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1080\/10428190903040048","article-title":"Report on the First International Workshop on interim-PET-scan in lymphoma","volume":"50","author":"Meignan","year":"2009","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"10.1016\/j.annonc.2025.11.006_bib18","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.annonc.2025.11.006_bib19","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/sim.4780121407","article-title":"How to establish equivalence when data are censored: a randomized trial of treatments for B non-Hodgkin lymphoma","volume":"12","author":"Com-Nougue","year":"1993","journal-title":"Stat Med"},{"issue":"S3","key":"10.1016\/j.annonc.2025.11.006_bib20","article-title":"Excellent outcome with interim PET adapted treatment reduction in elderly DLBCL pts with favourable prognosis: results of 288 pts treated in optimal >60 trial of the DSHNHL\/GLA","volume":"43","author":"Thurner","year":"2025","journal-title":"Hematol Oncol"},{"issue":"26","key":"10.1016\/j.annonc.2025.11.006_bib21","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1200\/JCO.20.00999","article-title":"Positron emission tomography-directed therapy for patients with limited-stage diffuse large B-cell lymphoma: results of Intergroup National Clinical Trials Network Study S1001","volume":"38","author":"Persky","year":"2020","journal-title":"J Clin Oncol"},{"issue":"27","key":"10.1016\/j.annonc.2025.11.006_bib22","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.annonc.2025.11.006_bib23","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1182\/blood-2017-02-766691","article-title":"FDG-PET-driven consolidation strategy in diffuse large B-cell lymphoma: final results of a randomized phase 2 study","volume":"130","author":"Casasnovas","year":"2017","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.annonc.2025.11.006_bib24","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1200\/JCO.2017.76.8093","article-title":"Positron emission tomography-guided therapy of aggressive non-Hodgkin lymphomas (PETAL): a multicenter, randomized phase III trial","volume":"36","author":"Duhrsen","year":"2018","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.annonc.2025.11.006_bib25","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1182\/blood.2020008750","article-title":"Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSA","volume":"137","author":"Le Gouill","year":"2021","journal-title":"Blood"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753425062647?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753425062647?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T13:26:30Z","timestamp":1778765190000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753425062647"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S0923753425062647"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2025.11.006","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Early positron emission tomography response-adapted treatment in low-risk diffuse large B-cell lymphoma: an open-label, multicenter, randomized, noninferiority phase III trial","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2025.11.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Society for Medical Oncology. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}